Opportunity Information: Apply for PAR 23 082
The National Institutes of Health (NIH) is offering a discretionary funding opportunity under a cooperative agreement mechanism (U01), titled "Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (Clinical Trial Optional)." The focus is Alzheimer disease (AD) and AD-related dementias (ADRD), specifically the ways sex differences shape how the brain ages, how disease risk develops, what clinical and biological phenotypes emerge, and how people respond to both drug-based and non-drug interventions. Because the U01 is a cooperative agreement, awardees should expect an active partnership with NIH program staff compared with a standard research grant, often involving coordination, shared milestones, and programmatic involvement to help drive the overall goals of the initiative.
The central scientific aim is to build integrative, multi-level research programs that connect basic biology with translational and, where appropriate, clinical research. The FOA emphasizes combining experimental and analytical approaches to create a more complete picture of how sex differences influence AD/ADRD trajectories from early brain aging through disease onset and progression. Applicants are encouraged to address heterogeneity: rather than treating AD/ADRD as a single uniform condition, the initiative pushes teams to explain why risk and treatment responsiveness can look different across individuals, and how sex-related biology contributes to those differences.
A key theme is interaction among genes, environment, and host factors, with particular attention to hormonal status, including both gonadal hormones and hormones produced within the brain. The FOA is looking for research that can explain how these influences interact across multiple levels of biological complexity. That includes work at the level of cells and molecular pathways, through tissues and organ systems (such as brain-immune or brain-vascular interfaces), and extending to human populations. In practice, this points to projects that can link mechanistic findings (for example, sex-linked differences in molecular signaling, immune responses, synaptic resilience, or protein clearance pathways) to measurable phenotypes in people, such as biomarker profiles, cognitive trajectories, or differential response to prevention and therapy.
The opportunity also stresses individualized prevention and responsiveness to interventions, meaning projects should ideally inform why prevention strategies or treatments might work better in some groups than others, and how sex differences contribute to that pattern. Importantly, the announcement is labeled "Clinical Trial Optional," so a project may include a clinical trial if it is scientifically justified, but it does not have to. This leaves room for a wide range of study designs, from preclinical mechanistic studies to human observational cohorts, biomarker-driven translational studies, and intervention research, as long as they are integrated and aligned with the overarching goal of understanding sex differences in AD/ADRD risk and treatment response.
Eligibility is broad and includes many types of U.S. organizations and governments: state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those categories as specified); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This broad eligibility signals an intent to encourage diverse institutions and communities to participate, including groups that may bring unique population data, community partnerships, or specialized scientific capabilities relevant to sex differences and AD/ADRD.
From the provided source details, the Funding Opportunity Number is PAR 23 082, the CFDA number listed is 93.866, and the opportunity is categorized under health-related research. The original closing date is February 21, 2025, and the record creation date is January 10, 2023. The notice does not provide an award ceiling or expected number of awards in the excerpt you shared, so applicants would need to consult the full FOA text and any linked NIH institute-specific budget guidance for details on allowable budgets, project periods, and program expectations. Overall, the opportunity is geared toward coordinated, integrative research that can move the field beyond simple comparisons between males and females and toward a deeper, mechanistic and clinically meaningful understanding of how sex-related biology shapes AD/ADRD risk and treatment outcomes.Apply for PAR 23 082
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-01-10.
- Applicants must submit their applications by 2025-02-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQ)
What is this NIH funding opportunity?
This is an NIH discretionary funding opportunity offered under a cooperative agreement mechanism (U01) titled "Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (Clinical Trial Optional)." It supports research on Alzheimer disease (AD) and AD-related dementias (ADRD), with a specific emphasis on how sex differences influence disease risk, biology, clinical presentation, and responsiveness to interventions.
What funding mechanism is being used and why does it matter?
The mechanism is U01, which is a cooperative agreement. Compared with a standard research grant, a cooperative agreement generally involves more active partnership with NIH program staff. Awardees should expect coordination with NIH, shared milestones, and programmatic involvement intended to help drive the overall goals of the initiative.
What is the main scientific focus of the FOA?
The FOA focuses on integrative, multi-level research programs that explain how sex differences shape brain aging, AD/ADRD risk, disease onset and progression, clinical and biological phenotypes, and responsiveness to both drug-based and non-drug interventions.
Which diseases and conditions are included?
The scope includes Alzheimer disease (AD) and AD-related dementias (ADRD), with attention to how sex-related biology affects trajectories from early brain aging through disease development and progression.
Is the goal simply to compare males and females?
No. The opportunity is geared toward moving beyond simple male-versus-female comparisons. The emphasis is on deeper, mechanistic and clinically meaningful explanations of how sex-related biology contributes to AD/ADRD risk and treatment outcomes.
What does "integrative, multi-level research" mean in this announcement?
It means connecting multiple levels of biology and evidence, such as molecular and cellular mechanisms, tissues and organ systems (including interfaces like brain-immune and brain-vascular), and human population-level phenotypes. The FOA encourages combining experimental and analytical approaches to build a more complete picture linking mechanism to measurable outcomes in people.
What kinds of outcomes or phenotypes does the FOA highlight?
Examples referenced include biomarker profiles, cognitive trajectories, and differential response to prevention strategies and therapies. The point is to connect mechanistic findings to measurable human phenotypes where appropriate.
What role do hormones play in the research priorities?
Hormonal status is specifically highlighted as a key host factor, including both gonadal hormones and hormones produced within the brain. The FOA is interested in how hormonal influences interact with genes, environment, and other host factors across biological levels.
Does the FOA emphasize genetics and environment as well?
Yes. A key theme is the interaction among genes, environment, and host factors. The announcement calls for research explaining how these influences interact across multiple levels of biological complexity in the context of sex differences and AD/ADRD.
Why does the FOA emphasize heterogeneity in AD/ADRD?
The initiative explicitly encourages applicants to address heterogeneity rather than treating AD/ADRD as a single uniform condition. Projects are expected to help explain why risk and treatment responsiveness differ across individuals and how sex-related biology contributes to those differences.
What kinds of research approaches are encouraged?
The FOA encourages combining experimental and analytical approaches and building programs that connect basic biology to translational and, where appropriate, clinical research. The description points to projects that can link mechanistic findings (for example, differences in molecular signaling, immune responses, synaptic resilience, or protein clearance pathways) to measurable human phenotypes.
Are clinical trials required?
No. The FOA is labeled "Clinical Trial Optional." A project may include a clinical trial if it is scientifically justified, but a clinical trial is not required.
If clinical trials are optional, what other study designs could fit?
Based on the description, the opportunity leaves room for preclinical mechanistic studies, human observational cohort studies, biomarker-driven translational studies, and intervention research, as long as they are integrated and aligned with the overarching goal of understanding sex differences in AD/ADRD risk and treatment response.
Does the FOA care about prevention and treatment responsiveness?
Yes. The opportunity stresses individualized prevention and responsiveness to interventions, with the aim of informing why prevention strategies or treatments may work better in some groups than others and how sex differences contribute to that pattern.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and governments, including state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (with exclusions as specified in the announcement text); for-profit organizations other than small businesses; and small businesses.
Are community-based or faith-based organizations eligible?
Yes. The eligibility list explicitly highlights faith-based or community-based organizations among additional eligible applicant categories.
Are minority-serving institutions specifically encouraged or eligible?
Yes. The FOA explicitly highlights several categories, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The eligibility section explicitly includes non-U.S. entities (foreign organizations) as eligible applicant categories.
Are U.S. territories or possessions included in eligibility?
Yes. The FOA highlights U.S. territories or possessions among the additional eligible applicant categories.
Are federal agencies eligible?
Yes. Eligible federal agencies are explicitly highlighted among the additional eligible applicant categories.
What is the Funding Opportunity Number for this announcement?
The Funding Opportunity Number is PAR 23 082.
What CFDA number is associated with this opportunity?
The CFDA number listed in the provided details is 93.866.
What is the application deadline?
The original closing date provided is February 21, 2025.
When was this opportunity record created?
The record creation date listed is January 10, 2023.
Is the award amount or award ceiling provided here?
No. The excerpt provided does not include an award ceiling or the expected number of awards. Applicants would need to consult the full FOA and any linked NIH institute-specific budget guidance for allowable budgets, project periods, and related expectations.
What should applicants expect in terms of NIH involvement after an award is made?
Because this is a U01 cooperative agreement, awardees should expect active partnership with NIH program staff, potentially including coordination across efforts, shared milestones, and programmatic involvement intended to help advance the initiative's overall goals.
What is the overall purpose of this initiative in practical terms?
Overall, it is designed to support coordinated, integrative research that clarifies how sex-related biology shapes AD/ADRD risk and trajectories and helps explain differential responsiveness to prevention and treatment, linking mechanistic biology to translational and potentially clinical insights.
Browse more opportunities from the same category: Health
Next opportunity: U.S. Higher Education Guidance Counselor Training Program
Previous opportunity: Mozambique Local Tuberculosis Response II
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 082
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 082) also looked into and applied for these:
| Funding Opportunity |
|---|
| Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) (R25 Clinical Trial Not Allowed) Apply for RFA HL 24 004 Funding Number: RFA HL 24 004 Agency: National Institutes of Health Category: Health Funding Amount: $317,000 |
| Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Coordination Center (U24 Clinical Trial Not Allowed) Apply for RFA HL 24 003 Funding Number: RFA HL 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed) Apply for PAR 23 073 Funding Number: PAR 23 073 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional) Apply for RFA HL 24 001 Funding Number: RFA HL 24 001 Agency: National Institutes of Health Category: Health Funding Amount: $281,250 |
| Planning for the TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (R34 Clinical Trial Not Allowed) Apply for RFA DE 23 014 Funding Number: RFA DE 23 014 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA HL 24 002 Funding Number: RFA HL 24 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,105,263 |
| Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) Apply for PAR 23 061 Funding Number: PAR 23 061 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional) Apply for PAR 23 060 Funding Number: PAR 23 060 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) Apply for PAR 23 062 Funding Number: PAR 23 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) Apply for RFA AG 24 001 Funding Number: RFA AG 24 001 Agency: National Institutes of Health Category: Health Funding Amount: $2,925,000 |
| Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) Apply for PAR 23 084 Funding Number: PAR 23 084 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) Apply for PAR 23 101 Funding Number: PAR 23 101 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) Apply for PAR 23 087 Funding Number: PAR 23 087 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required) Apply for RFA MH 23 170 Funding Number: RFA MH 23 170 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) Apply for PAR 23 105 Funding Number: PAR 23 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) Apply for PAR 23 102 Funding Number: PAR 23 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required ) Apply for PAR 23 103 Funding Number: PAR 23 103 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PROPEL Youth and Gender (Round 3): Promoting Results and Outcomes through Policy and Economic Levers Apply for 7200AA22APS00002 03 Funding Number: 7200AA22APS00002 03 Agency: Agency for International Development Category: Health Funding Amount: $20,000,000 |
| AHRQ Small Research Projects to Advance the Science of Primary Care (R03) Apply for PA 23 115 Funding Number: PA 23 115 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 23 002 Funding Number: RFA MD 23 002 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 082", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.